<code id='A3B0913644'></code><style id='A3B0913644'></style>
    • <acronym id='A3B0913644'></acronym>
      <center id='A3B0913644'><center id='A3B0913644'><tfoot id='A3B0913644'></tfoot></center><abbr id='A3B0913644'><dir id='A3B0913644'><tfoot id='A3B0913644'></tfoot><noframes id='A3B0913644'>

    • <optgroup id='A3B0913644'><strike id='A3B0913644'><sup id='A3B0913644'></sup></strike><code id='A3B0913644'></code></optgroup>
        1. <b id='A3B0913644'><label id='A3B0913644'><select id='A3B0913644'><dt id='A3B0913644'><span id='A3B0913644'></span></dt></select></label></b><u id='A3B0913644'></u>
          <i id='A3B0913644'><strike id='A3B0913644'><tt id='A3B0913644'><pre id='A3B0913644'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge